Non-invasive Prenatal Testing Market Expected to Grow at a CAGR of 10.70% During 2021-2026 – Stillwater Current

According to the latest IMARC group report, entitled “Non-invasive Prenatal Testing Market Report: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2021-2026,“The global non-invasive prenatal testing market has shown strong growth during the period 2015-2020. Looking ahead, IMARC Group expects the global non-invasive prenatal testing market to grow at a CAGR of 10.70% in 2021-2026. The non-invasive prenatal test (NPNT) refers to a type of non-invasive prenatal screening used to determine whether a fetus is at increased risk of being born with genetic abnormalities. Some pieces of DNA from the fetus usually pass into the bloodstream of the pregnant person, called cell-free DNA. This test analyzes the genetic information of cell-free DNA to determine the health of the fetus. NIPT involves the use of a needle and syringe to draw blood and eliminates the requirement of traditional invasive procedures. The test can be done after nine weeks of pregnancy and is used to diagnose genetic disorders such as Down, Edwards, and Turner syndrome.

We regularly monitor the direct effect of COVID-19 on the market, as well as the indirect influence of related industries. These observations will be incorporated into the report.

Request a free copy of this report: https://www.imarcgroup.com/non-invasive-prenatal-testing-market/requestsample

Global non-invasive prenatal testing market trends:

The market is primarily driven by the increasing prevalence of fetal chromosomal abnormalities across the world. As a result, NIPT is increasingly used by healthcare professionals to accurately diagnose genetic disorders during the first trimester of pregnancy. It largely replaces the costly and risky invasive amniocentesis and chorionic villus sampling (CVS) procedures due to the convenience associated with the non-invasive approach to testing, which in turn creates a positive outlook for the market. . Along with developments in DNA sequencing technologies, regenerative drugs, and breakthroughs in molecular research, these disorders are further treated effectively in the early stages of fetal development. In addition to this, the growing awareness among the masses of the importance of antenatal care and advancements in the health sector that facilitate the treatment of the fetus during the gestation period act as major growth factors. In addition, increasing maternal age can often lead to life-threatening pregnancy complications, such as high risks of miscarriage and genetic abnormalities. As a result, pregnant patients are increasingly opting for prenatal testing to diagnose their condition at an early stage.

Buy the full report with table of contents: https://www.imarcgroup.com/non-invasive-prenatal-testing-market

Key market segmentation:

Competitive landscape:

The competitive landscape of the market has been studied in the report along with detailed profiles of major players. Some the best companies in the non-invasive prenatal testing industry being Agilent Technologies, Inc., Berry Genetics, Inc., BGI Genomics Co., Ltd., Eurofins Scientific Services Limited, F. Hoffmann-La Roche Ltd, GE Healthcare, Igenomix, Illumina Inc., Laboratory Corporation, Natera Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc. and Yourgene Health plc.

Breakdown by product type:

On the basis of Product Type, the market has been divided into Consumables and Instruments.

Breakdown by type of test:

  • Maternity 21
  • Harmony
  • Panaroma
  • To verify
  • HELLO
  • Others

Based on the type of test, the market has been divided into materni 21, harmony, panaroma, verifi, NIFTY and others.

Breakdown by technology:

On the basis of technology, the market has been categorized into NGS, WGS, and others.

Breakdown by type of test:

  • Ultrasonic detection
  • Biochemical screening tests
  • Cell-free DNA in maternal plasma tests
  • Fetal cells in maternal blood tests
  • Others

On the basis of test type, the market has been categorized into Ultrasonic Detection, Biochemical Screening Tests, Cell-free DNA in Maternal Plasma Tests, Fetal Cells in Maternal Blood Tests, and others.

Breakdown by application:

  • Down’s syndrome
  • Microdeletion syndrome
  • Others

Based on Application, the market has been segmented into Down Syndrome, Microdeletion Syndrome, and others.

Breakdown by end user:

  • Hospitals
  • Diagnostic laboratories
  • Others

On the basis of the end user, the market has been divided into hospitals, diagnostic laboratories, and others.

Breakdown by region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Geographically, the market has been separated into North America (United States and Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Russia and others), Asia-Pacific (China, Japan, India , Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico and others) and the Middle East and Africa.

About Us:

The IMARC group is a leading market research company providing management strategies and market research worldwide. We partner with clients across industries and regions to identify their most exciting opportunities, address their most critical challenges and transform their businesses.

IMARC’s information products include key business, scientific, economic and technological developments for business leaders in pharmaceutical, industrial and high-tech organizations. Market forecasting and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology, and new processing methods are at the top of the market. business expertise.

Contact us:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Website: https://www.imarcgroup.com/
Email: [email protected]
United States: + 1-631-791-1145
Follow us on twitter: @imarcglobal
Linkedin: https://www.linkedin.com/company/imarc-group

Comments are closed.